Characterization of early host responses in adults with dengue disease. by Tolfvenstam, Thomas et al.
Tolfvenstam, T; Lindblom, A; Schreiber, MJ; Ling, L; Chow, A; Ooi,
EE; Hibberd, ML (2011) Characterization of early host responses in
adults with dengue disease. BMC Infect Dis, 11. p. 209. ISSN 1471-
2334 DOI: 10.1186/1471-2334-11-209
Downloaded from: http://researchonline.lshtm.ac.uk/292311/
DOI: 10.1186/1471-2334-11-209
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
Characterization of early host responses in adults
with dengue disease
Thomas Tolfvenstam1,2*, Anna Lindblom1, Mark J Schreiber3, Ling Ling1, Angelia Chow4, Eng Eong Ooi4 and
Martin L Hibberd1
Abstract
Background: While dengue-elicited early and transient host responses preceding defervescence could shape the
disease outcome and reveal mechanisms of the disease pathogenesis, assessment of these responses are difficult
as patients rarely seek healthcare during the first days of benign fever and thus data are lacking.
Methods: In this study, focusing on early recruitment, we performed whole-blood transcriptional profiling on
denguevirus PCR positive patients sampled within 72 h of self-reported fever presentation (average 43 h, SD 18.6
h) and compared the signatures with autologous samples drawn at defervescence and convalescence and to
control patients with fever of other etiology.
Results: In the early dengue fever phase, a strong activation of the innate immune response related genes were
seen that was absent at defervescence (4-7 days after fever debut), while at this second sampling genes related to
biosynthesis and metabolism dominated. Transcripts relating to the adaptive immune response were over-
expressed in the second sampling point with sustained activation at the third sampling. On an individual gene
level, significant enrichment of transcripts early in dengue disease were chemokines CCL2 (MCP-1), CCL8 (MCP-2),
CXCL10 (IP-10) and CCL3 (MIP-1a), antimicrobial peptide b-defensin 1 (DEFB1), desmosome/intermediate junction
component plakoglobin (JUP) and a microRNA which may negatively regulate pro-inflammatory cytokines in
dengue infected peripheral blood cells, mIR-147 (NMES1).
Conclusions: These data show that the early response in patients mimics those previously described in vitro,
where early assessment of transcriptional responses has been easily obtained. Several of the early transcripts
identified may be affected by or mediate the pathogenesis and deserve further assessment at this timepoint in
correlation to severe disease.
Background
Dengue virus (DENV) is endemic throughout the tropics
and in many subtropical parts of the world, causing sig-
nificant human morbidity and mortality [1]. An under-
standing of the host response, as obtained from
genome-wide transcriptional profiling of dengue infec-
tion may reveal unique patterns pertaining to specific
disease outcomes and identify molecular mechanisms
that could be targeted pharmacologically [2,3] and a
number of studies of the host transcriptional responses
to DENV infection have been performed. Comparing
the results from in-vitro DENV-infected cells; HUVEC
[4], non-small lung cancer cells [5], HepG2 [6,7]; pri-
mary human immune cells [8] and muscle satellite cells
[9]; to whole blood or isolated mononuclear cells from
DENV-infected patients [10-14], the first studies reports
abundant transcripts related to innate immunity while
the latter largely report non-immune related transcripts
of ER-stress, oxidative metabolism and signal transduc-
tion. However, the human studies sampled patients at
the time of hospital admission or after 4-5 days of ill-
ness, focusing on differences between clinical pheno-
types. We hypothesized that earlier assessment following
symptom presentation would be required to characterize
the in-vivo dengue innate immune response and that
the early host responses may reflect components of the
disease pathogenesis.
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Methods
To characterize the early transcriptional response to
DENV-infection in-vivo, we performed transcriptional
profiling on 31 clinically undifferentiated DENV RT-
PCR positive patients sampled within 72 h, 4-7 days and
3-4 weeks after self-reported fever onset, and compared
the signatures with controls consisting of 26 matched
febrile patients of other etiology (table 1). The time
point of the 1st, 2nd and 3rd sampling was regarded as
acute disease, defervescence and convalescence, respec-
tively. All patients were identified in the early dengue
infection and control study [15] in Singapore. The study
was conducted in accordance with the declaration of
Helsinki and approved by the NHG ethical review board
(DSRB B/05/013). Individuals eligible for inclusion gave
their written consent to participate in the study, were
≥18 years of age and presented ≤72 h from onset of
fever ≥38°C. None of the DENV RT-PCR positive
patients progressed to fulfill the criteria for severe den-
gue [16], while 20 of 31 (65%) were subsequently hospi-
talized after inclusion, the main admission criteria being
thrombocytopenia [17] (table 2). Seven of these patients
reported occurrence of mucosal bleeding. DENV-RNA
was quantified by a Taqman-based PCR [18] after serum
extraction (QIAamp Viral RNA mini kit, Qiagen). The
mean viral copy number in the dengue DENV RT-PCR
positive samples were 2.99 × 109 copies/mL (range 5.29
× 104-3.15 × 1010). Viral serotype was determined by
sequencing [19], the most common serotype being
DENV3 (20 patients) followed by DENV1 (10 patients)
and DENV2 (one patient). There was no finding of
DENV4. DENV-specific IgG was detected by enzyme
immunosorbent assay (EIA) (Panbio). Total whole-blood
RNA (collected in pax-gene tubes, Becton Dickinson)
was extracted (PAX-gene RNA kit, Qiagen) and ampli-
fied (Illumina® TotalPrep™ RNA Amplification Kit,
Ambion) before hybridization to a gene-expression array
containing 23,961 RefSeq gene sequences (Illumina
HumanRef-8 V1BeadChip, Illumina) [20]. Data was
extracted (Bead Studio Software, Illumina) and normal-
ized using one color array data (GenespringGX software,
Silicon Genetics). Data transformation was corrected for
low signal, with values recorded <0.01 increased to the
minimum (0.01). Per-chip (mean) normalization
accounted for chip variability by dividing all of the mea-
surements on each chip by a 50th percentile value. Per-
gene normalization accounted for variability between
probe sets for different genes. Genes that were not con-
fidently detected in at least two samples were excluded,
leaving 10,229 genes available for differential expression.
Differentially expressed genes were selected from the
normalized data using significance analysis of microar-
rays (SAM) [21] using a cutoff of 5%, with an additional
filter of a minimum 2-fold difference in expression
between groups, together with a minimum detection
threshold for the gene in at least half of the patients in
the smallest group. Pathway-analysis (IPA software,
Ingenuity Systems) was performed to analyze enriched
or less-abundant gene lists and the significance of the
association was measured using right-tailed Fisher’s
exact test. The microarray data was deposited in NCBI’s
Gene Expression Omnibus [22] and accessible through
GEO Series accession number [GSE28405]. Secreted
mediators corresponding to hybridization-identified
highly enriched transcripts (CCL2 (MCP-1), -8 (MCP-2),
CXCL10 (IP-10) and CCL3 (MIP-1a)) were investigated
for differential expression using Taqman assays (Applied
Biosystems) [23] and the corresponding proteins quanti-
tated in serum by Luminex bead-array (BioRad)(for
CXCL10 also an EIA, R&D Systems) as per manufac-
turer’s instructions. Taqman data were normalized for
RNA loading levels by using 18 s quantitation as a refer-
ence and exported using SDS RQ Manager Software
(Applied Biosystems). Relative (RQ) levels were exported
Table 1 Characteristics of patients sampled for whole-blood RNA
DENV RT-PCR positive DENV RT-PCR negative
N 31 26
Duration of fever to 1st sampling, hours 43 (13-72) 27 (3-72)
Age, years 43 (23-66) 43 (21-67)
Male, no. (%) 16 (52) 14 (54)
DENV IgG positive at inclusion, no. (%) 10/31 (32) 11/26 (42)
Duration of symptoms to recovery, days 11 (3-22) 6 (2-21)
Data are mean (range) values. DENV, dengue virus; the time point of the 2nd sampling was regarded as defervescence. N/A, not applicable.
Table 2 Sequential hematological parameters of DENV
RT-PCR positive patients
1st
sampling
2nd
sampling
3rd
sampling
Time from last sampling,
hours
N/A 79 (48-144) 363 (216-
672)
White blood cell count,
109/L
3.5 (1.2-8.8) 2.9 (1.3-6.5) 6.2 (2.4-9.8)
Hematocrit, (%) 42.4 (33.4-
53.3)
43.7 (32.0-
58.5)
40.3 (23.1-
62.2)
Thrombocyte count, 109/L 159 (17-309) 84 (8-237) 333 (88-625)
Data are mean (range) values, unless otherwise indicated.
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and analyzed for significance using the Wilcoxon Rank
Sum Test (assuming the data were non-normally distrib-
uted). Fold-change analysis was based on median levels.
Results
By comparing samples drawn from DENV RT-PCR
positive patients ≤72 h (on average sampled 43 h, SD
18.6 h, after self-reported fever debut), to autologous
samples drawn 3-4 weeks after fever debut, we identified
1,378 significantly different abundant gene transcripts of
which 803 were up-regulated and 575 down-regulated,
relative to the convalescent sample (Additional file 1).
Canonical pathway analyses of the significantly enriched
genes revealed strongly significant up-regulated immune
pathways as outlined in Figure 1a. The top two most
significant canonical pathways were interferon (IFN)-
signaling and pathways related to pattern recognition
receptors. Other strongly over-represented innate
immune responses were complement activation, TREM1
signaling, and communication between the innate and
adaptive immune response. Among the down-regulated
genes (n = 575) the top canonical pathways were T-cell
associated pathways reflecting the relative up regulation
of adaptive immunity during convalescence (Figure 1b).
By comparing samples drawn from DENV RT-PCR
positive patients 4-7 days (on average sampled 122 h,
SD 30.8 h, after self-reported fever debut), to autologous
samples drawn 3-4 weeks after fever debut, we could
identify 2,677 differentially abundant genes of which
2,020 were up regulated and 657 down regulated (Addi-
tional file 2). Pathway analyses of the up regulated tran-
scripts showed no immunity-related genes (Figure 1c).
Figure 1 Pathway analysis of differentially expressed transcripts in samples from patients with a) acute dengue as compared to
patients with convalescent dengue (1,378 significantly enriched transcripts), b) acute dengue as compared to patients with
convalescent dengue (575 significantly less enriched transcripts), c) dengue disease at defervescence as compared to patients with
convalescent dengue disease (2,020 significantly enriched transcripts), d) acute dengue as compared to febrile patients with non-
dengue disease (236 significantly enriched transcripts). Shown are the top five canonical pathways identified by unsupervised pathway
analysis of filtered microarray data. The strength of the statistical association is indicated by the length of the bars. The ratio reflects the
proportion of gene elements on the differentially expressed gene list that belong the specific canonical pathways.
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The dominating pathways relate to biosynthesis and
metabolism functions. The statistical pathway associa-
tion for the under-expressed genes was weak (data not
shown). By comparing samples drawn from febrile
DENV RT-PCR positive patients ≤72 h to samples
drawn from febrile DENV RT-PCR negative patients
≤72 h (on average sampled 27 h, SD 24.0 h, after self-
reported fever debut), we identified 536 significantly dif-
ferently abundant gene transcripts of which 236 were
enriched and 300 downregulated (Additional file 3).
Canonical pathways analyses on the transcripts that
were significantly enriched are outlined in Figure 1d. As
in the analysis comparing patients with acute versus
convalescent dengue disease, also here, the three most
enriched canonical pathways that came up were patho-
gen recognition, IFN-signaling and complement activa-
tion. Pathway analysis of transcripts that were
significantly less abundant found only canonical path-
ways with weak significant associations (data not
shown). The most expressed transcripts and the asso-
ciated pathways overlapped between the datasets, but
fewer IFN-signaling and pathogen recognition associated
transcripts were significantly expressed when comparing
the datasets of acute dengue to non-dengue febrile ill-
ness. Several downstream genes in the type-1 IFN-sig-
naling pathway were up-regulated in both datasets while
type-2 IFN-signaling genes were overrepresented in the
acute versus convalescent dengue disease comparison.
Enrichment of toll-like receptor (TLR) 7 and MDA-5
transcripts was seen in both datasets. In the acute versus
convalescent dengue disease comparison, the TLR6
receptor was over-expressed together with genes from
the retinoic acid-inducible gene-I-like receptor (RLR)
signaling pathway and the nod-like receptor (NLR) sig-
naling pathway. Transcripts from genes clustering in the
peroxisome proliderator-activated receptor (PPAR) sig-
naling pathway were more significantly enriched when
comparing acute dengue to non-dengue than when
comparing acute versus convalescent dengue disaease.
Among the transcripts representing secreted mediators,
CCL2 was the most over-expressed transcript in both
datasets, possibly due to an active feedback loop invol-
ving CCR1, JAK1 and STAT1/STAT3. In addition, tran-
scripts of two other chemokines, CCL8 and CXCL10
and the antimicrobial peptide b-defensin 1 (DEFB1)
were highly expressed in both datasets together with
many components of the chemotactic network. Other
highly expressed transcripts present in both datasets
were; JUP (plakoglobin), NMES1 and CCNA1. Compar-
ing whole genome expression profiles between patients
with acute versus convalescent dengue disease indicated
significant abundance of transcripts of the chemokines
CCL2 (4,287 fold), CCL8 (160 fold), CXCL10 (30 fold)
and CCL3 (17 fold) during acute dengue. All except
MIP-1a were replicated, with smaller fold changes, in
the comparison between febrile patients with acute den-
gue disease versus non-dengue disease. PCR quantifica-
tion of the same transcripts in patients with acute
versus convalescent dengue disease showed highly ele-
vated fold changes for CCL2, -8 and CXCL10 but a
more modest enrichment of MIP-1a at fold change 3.5
(table 3). Protein measurements of these chemokines in
consecutive serum samples from the DENV RT-PCR
positive patients showed significantly higher concentra-
tions in acute dengue compared to convalescent dengue
disease in correspondence with gene transcript fold
changes (table 4). Comparing samples from DENV RT-
PCR positive patients based on DENV-specific IgG sta-
tus at inclusion (≤72 h after self-reported fever debut),
one transcript was found significantly differently abun-
dant, PRDX2 (accession NM_181738, 2-fold enriched in
the ten DENV-IgG positive patients). Replicating this
comparison of the autlogous samples collected at 4-7
days and 3-4 weeks after self-reported fever debut, four
(all enriched in DENV-IgG positive patients) (Additional
file 4) and 31 (18 enriched in DENV-IgG positive
patients) (Additional file 5), were found significantly dif-
ferently abundant, respectively. Pathway analysis of all
these transcripts found only weakly significant canonical
pathway associations (data not shown).
Discussion
Taken together, at this previously unassessed early stage
of dengue disease the innate immune responses predo-
minate, with the most significant canonical pathways
being IFN-signaling, pattern recognition signaling and
complement activation, both in relation to autologous
transcripts in convalescence and to whole blood tran-
scripts in non-dengue febrile illnesses at a similar phase
following fever onset. In the convalescent phase of den-
gue disease, pathways related to adaptive immune
responses are active, rendering these genes to appear
down-regulated at the acute phase and in concordance
with previous reports on transcripts derived from den-
gue disease in or just before defervescence [10-14], non-
immune canonical pathways dominate. Interestingly,
Table 3 Differential expression measured by taq-man low
density array in DENV RT-PCR positive patients
Fold change
Gene Acute dengue relative to
convalescent dengue
Dengue at defervescence
relative to convalescent
dengue
CCL2 88.06 3.57
CCL8 169 3.48
CXCL10 44.26 6.64
CCL3 3.71 6.32
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many of the responses seen in acute dengue in relation
to the convalescent baseline were replicated when com-
paring to other non-dengue febrile illnesses, indicating a
more prominent IFN-response, specific to dengue dis-
ease, and a selective utlization of TLR7, MDA5 and
OAS. We do not have information of the etiology of the
non-dengue febrile controls, but etiological search in
patients enrolled later in the same cohort have shown
that viral infections such as influenza, adenovirus and
metapneumovirus are common among the DENV RT-
PCR negative controls. IFN-responses arise hours after
viremia is established and are likely of great importance
for the control of viral replication. The IFN-response in
dengue infection have been shown to be activated
through two main pathogen recognition families; the
TLRs and the RLRs. Of the TLRs, TLR7 in dendritic
cells has been shown to interact with DENV RNA lead-
ing to viral fusion and uncoating processing that in the
end activated a type-1 IFN-response [24]. TLR3 was also
shown to have a role in the regulation of the inflamma-
tory response in dengue infected umbilical vein
endothelial cells [4]. When we compared the acute sam-
ples with the samples collected at convalescence in our
dengue positive patients we saw an up regulation of
TLR7 and IRF7 which indicates an activation of the
TLR7 signalling pathway. TLR7 is an intracellular recep-
tor that senses microbial nucleic acids and via IRF7
induces a strong type-1 IFN-response, particularly IFNa
[25]; while it can also induced a type-1 IFN-response via
NFB [26]. RLR activation was also seen when compar-
ing acute versus convalecent samples in the DENV RT-
PCR positive patients, with the genes RIG1 and MDA5
upregulated. A recent study from Fredericksen et al
demonstrated that RIG1 and MDA5 induce an IFN-
response in West Nile virus-infected fibroblasts by acti-
vation of IRF3 [27]. They also show that RIG1 primes
an early IFN-response while MDA5 is more involved in
the second phase of IFN-dependent gene expression.
Both RIG1 and MDA5 have also been shown to be acti-
vated in double RIG1/MDA5 knockout mouse fibro-
blasts [28,29]. Interestingly, RIPK2 (RIP2) was also
identified as an over expressed gene indicating activation
of the NLR signalling pathway. NOD1 and NOD2,
members of the NLR protein family, are activated by
specific bacterial peptides, and via RIPK2 induce NFB
activation [30]. There are no earlier reports on virus
induced NLR activation. Transcripts clustering to the
PPAR pathway were also among the most significantly
enriched comparing dengue to non-dengue. PPARg has
been shown to play a critical role in the control of adi-
pocyte differentiation and lipid metabolism, and also
immunity and the barrier functions of epithelial and
endothelial cells; in dengue disease this could be a
response to epithelial stress [31,32]. Furthermore,
among the most highly enriched gene transcripts is JUP
(plakoglobin), that encode a protein that forms part of
desmosomes and intermediate junctions in endothelial
cells, wich could indicate that some transcripts were
derived from affected endothelial cells. In fact, high
numbers of detached endothelial cells in peripheral
blood has been obseved in the acute phase of dengue
[33]. DEFB1 was another highly enriched transcript
which encodes an antimicrobial peptide, b- defensin 1,
that has mostly been studied in the context of epithelial
protection against HIV [34]. Also among the highly
enriched transcripts were genes of the secreted media-
tors CCL2, CCL8, CXCL10 and CCL3, whose proteins
were also found to be adundant in patient serum (Table
2). These have been observed before in dengue disease
and MCP-1 could well participate in the pathogenesis of
vascular leakage by its effect on endothelial tight junc-
tions [35,36]. Other genes that were significantly
enriched but did not cluster to any canonical pathway
were NMES1 and CCNA1. While CCNA1 is a cyclin
which probably mediates cell cycle arrest to prevent
virus replication in infected cells, little is known about
the gene NMES1. A recent study has identified that the
transcript is a primary functional microRNA (miR-147)
which was expressed in murine macrophages upon
TLR-stimulation [37]. It was shown to negatively regu-
late inflammatory cytokine expression in these cells. As
dengue virus is believed to primarily replicate in cells of
monocyte/macrophage lineage, NMES1 expression may
be important to moderate the pro-inflammatory cyto-
kine release from these cells, especially as these are
potential mediators of pathology. Comparing dengue
patients with different DENV-serostatus at inclusion
rendered a surprisingly small number of differentially
Table 4 Chemokine concentrations in consecutive serum samples from DENV RT-PCR positive patients
Median concentration in serum (pg/mL)
Acute dengue disease Dengue at defervescence Convalescent dengue p-value* acute vs convalescence
CCL2 268 104 62 <0.0001
CCL8 668 325 110 <0.0001
CXCL10 10750 7013 451 <0.0001
CCL3 8 nd nd
nd = under limit of detection, *Wilcoxon matched-pairs signed-ranks test.
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expressed genes with no significant pathway clustering.
On the individual gene level PRDX2, an antioxidant
enzyme was enriched in the acute stage of secondary
DENV infection, while at defervesence, CCR2 was
among the transcripts seen upregulated in secondary
infection. Sierra et al. addressed this issue by examining
in-vitro infected PBMC from immune and non-immune
individuals and showed expression of CCL2 to be highly
dependent on previously infecting serotype at 24 h post
infection [38]. CCL2 was not an found an enriched tran-
script in acute secondary infection in our material but
the number of patients in each group in this specific
comparison was small (ten patients were DENV RT-
PCR and DENV-IgG positive) and information of pre-
vious infecting serotype was lacking, thus this specific
assessment should be perfomed in a larger cohort to
allow further speculation on these genes in the context
of dengue pathogenesis.
Conclusions
In summary, early DENV-induced transcriptional host
responses in-vivo are predominatly involving innate
immune responses and overlaps to a large extent with
those described in in-vitro, where early transcriptional
assessment post-infection has been easily obtained. Sev-
eral of the early transcripts identified deserve further
assessment in correlation to severe disease.
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Additional file 1: The top 100 differentially abundant transcripts in
samples from patients with acute dengue relative to samples from
patients with convalescent dengue. A table outlining the top 100
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patients with convalescent dengue.
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disease.
Additional file 4: Differentially abundant transcripts in samples
taken at defervescence from DENV RT-PCR/DENV-IgG positive
patients at inclusion relative to DENV RT-PCR positive/DENV-IgG
negative patients at inclusion. A table outlining the differentially
abundant transcripts in samples taken at defervescence from DENV RT-
PCR/DENV-IgG positive patients at inclusion relative to DENV RT-PCR
positive/DENV-IgG negative patients at inclusion.
Additional file 5: Differentially abundant transcripts in samples
taken at convalescence from DENV RT-PCR/DENV-IgG positive
patients at inclusion relative to DENV RT-PCR positive/DENV-IgG
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